Gene mutation can allow proteins to gather, spark tumor growth
September 7, 2012 by Julie Deardorff in Cancer
Prostate cancer is generally treated as if it's a single disease. But researchers have discovered a new type of the cancer that appears to affect 15 percent of patients, a finding that paves the way for better diagnosis and more targeted therapies down the road.
The new pathway for prostate cancer development was discovered after a team of scientists identified unique mutations in a gene known as SPOP (pronounced 'S-Pop') while examining patient tumors. These aberrations may lead to a dangerous accumulation of proteins that spark tumor growth, forming a distinct kind of cancer, according to the study, published in the journal Nature Genetics.
The discovery of a second way for cancer to grow means we might one day "think of prostate cancer not as one disease but as a collection of molecularly defined subtypes, similar to breast and lung cancer," said Dr. Mark Rubin, vice chair for experimental pathology at Weill Cornell Medical College and a co-senior investigator of the study.
Along with previous research, the study is helping flesh out the overall genetic landscape of prostate cancer - the most common cancer in men with the exception of skin cancer.
About one-sixth of men will be diagnosed with prostate cancer in their lifetime; two-thirds when they are older than 65. Prostate cancer is the second leading cause of cancer deaths in men.
Some speculate that the finding of an SPOP mutation may be one of the breakthroughs oncologists have been seeking. "Knowing what these mutations mean may give us huge clues about how the patient's cancer will progress and how they might be best treated in the future," said study co-author Christopher Barbieri, chief resident in urology at Weill Cornell who spent a research year in Rubin's laboratory.
About half of all prostate cancers are characterized by the presence of so-called ETS fusion genes. A gene fusion occurs when two genes located in different parts of the genome become attached together, leading to a new function.
The new subtype of prostate cancer is defined by two factors: the presence of a mutation in the SPOP gene and the loss of DNA in an area harboring another gene.
"Alterations in these two major gatekeepers lead to a cascade of downstream events that make these tumors distinct from other prostate cancers," said Rubin, who noted that SPOP mutations and fusion genes never occur in the same tumor, implying two distinct molecular classes of prostate cancer.
The SPOP gene belongs to a family whose job is to regulate other proteins by tagging or marking them for disposal. The team discovered the mutations occur where the SPOP protein binds to the other proteins it should tag.
"That suggests that there might be an accumulation of proteins in the cell that aren't cleaned out and this might lead to cancer growth, or the mutations could be removing proteins that help prevent unchecked cell growth," said Rubin.
Rubin predicted that within a year, men already confirmed with prostate cancer will be able to get tested to see what kind of subtype of prostate cancer they have and then receive tailor-made treatment. Rubin predicts future screening tests will include panels of such cancer specific markers to ensure accurate diagnosis of cancer.
Still, others say that although the discovery is exciting, the test wouldn't be clinically available for quite some time - if ever. Additionally, it would never be used as a screening tool because it's present in only a small portion of all prostate cancers.
Journal reference:
Nature Genetics
(c)2012 Chicago Tribune
Distributed by MCT Information Services
-
Distinct molecular subtype of prostate cancer identified
May 20, 2012 |
not rated yet |
0
-
Prostate cancer's multiple personalities revealed
Nov 03, 2010 |
not rated yet |
0
-
Gene fusion discovery may lead to improved prostate cancer test
Apr 09, 2009 |
not rated yet |
0
-
Newly discovered gene fusion may lead to improved prostate cancer diagnosis
Jul 23, 2009 |
not rated yet |
0
-
Scientists identify KRAS rearrangements in metastatic prostate cancer
Apr 03, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
3 hours ago
-
If you became brain-dead, would you want them to pull the plug?
20 hours ago
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
ASCO: combo antibody therapy effective for melanoma
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer
15 hours ago |
not rated yet |
0
Risk factors ID'd for poor cutaneous cell CA outcomes
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer
16 hours ago |
not rated yet |
0
|
Physical & emotional impairments common, often untreated in people with cancer
A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...
Cancer
20 hours ago |
not rated yet |
0
Calif. doc with 'cancer cure' gets 14 years prison (Update)
(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.
Cancer
21 hours ago |
not rated yet |
0
New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
23 hours ago |
not rated yet |
0
|
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
Melon focus headband turns to Kickstarter for rollout plans
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
Temporal processing in the olfactory system
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
Individuals who drink heavily and smoke may show 'early aging' of the brain
Treatment for alcohol use disorders works best if the patient actively understands and incorporates the interventions provided in the clinic. Multiple factors can influence both the type and degree of neurocognitive abnormalities ...